Transport
The Milton S Hershey Medical Center
The Milton S Hershey Medical Center was paid $78.95M by Medicaid between Jan 2018 and Dec 2024, across 740 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 19% of everything it billed.
33Billing provider infoTHE MILTON S HERSHEY MEDICAL CENTER
HERSHEY, PA 17033
HERSHEY, PA 17033
33aNPI1568435477assigned 02/10/2006
33bProvider typeLand Ambulance
28Total paid$78.95M
24GClaims1,567,535
24DCodes billed740
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Land Ambulance providers in Pennsylvania
Rank by total paid#2 of 334
Median peer was paid$174K
This provider vs. median453×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCKENNA, DONALD controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,126 | $386K | |
| 2019 | 13,287 | $474K | |
| 2020 | 204,451 | $7.73M | |
| 2021 | 778,889 | $36.16M | |
| 2022 | 225,578 | $11.72M | |
| 2023 | 191,896 | $11.91M | |
| 2024incomplete | 147,308 | $10.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 19% | 305,789 | 278,012 | $14.75M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 25,509 | 24,705 | $9.21M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.0% | 28,225 | 27,499 | $7.11M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 8,549 | 8,178 | $4.64M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.8% | 72,806 | 64,361 | $2.18M |
| G0378 | Hospital observation service, per hour | 2.2% | 2,146 | 2,005 | $1.72M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.6% | 173 | 172 | $1.29M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.4% | 1,278 | 1,257 | $1.11M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 12,371 | 11,923 | $1.06M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 7,167 | 5,424 | $945K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 1.1% | 2,654 | 2,210 | $906K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.0% | 382 | 322 | $826K |
728 more codes
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 2,613 | $786K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,831 | $783K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 2,261 | $761K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,722 | $749K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,856 | $706K |
| 93304 | <1% | 1,807 | $696K | |
| 59025 | Fetal non-stress test | <1% | 3,872 | $677K |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 2,834 | $664K |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | <1% | 173 | $612K |
| 95782 | <1% | 687 | $606K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,377 | $601K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,925 | $589K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 7,945 | $542K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,019 | $516K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 3,059 | $505K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 707 | $453K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,632 | $438K |
| 76770 | <1% | 4,449 | $424K | |
| 94010 | <1% | 3,654 | $413K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 6,509 | $398K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 754 | $396K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 1,703 | $389K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,855 | $387K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 985 | $386K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 4,199 | $344K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,840 | $338K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,332 | $318K |
| 95117 | <1% | 7,277 | $299K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,362 | $283K |
| A0425 | Ground mileage, per statute mile | <1% | 6,520 | $274K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,783 | $269K |
| 92557 | <1% | 2,522 | $267K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,646 | $259K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 303 | $241K |
| 94060 | <1% | 1,082 | $233K | |
| 64642 | <1% | 630 | $233K | |
| 80053 | Comprehensive metabolic panel | <1% | 33,506 | $231K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,284 | $230K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 3,202 | $226K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,477 | $225K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,501 | $217K |
| J2323 | Injection, natalizumab, 1 mg | <1% | 242 | $217K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 9,887 | $216K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,689 | $211K |
| 92060 | <1% | 5,160 | $211K | |
| 95816 | <1% | 828 | $209K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,352 | $200K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 241 | $197K |
| 93226 | <1% | 2,028 | $197K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,186 | $194K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,568 | $188K |
| 36415 | Collection of venous blood by venipuncture | <1% | 63,578 | $185K |
| 86900 | <1% | 2,644 | $182K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 779 | $181K |
| 97803 | <1% | 3,296 | $179K | |
| 92567 | <1% | 6,906 | $175K | |
| 92587 | <1% | 740 | $175K | |
| 36430 | <1% | 586 | $168K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,763 | $150K |
| 20610 | <1% | 962 | $150K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,269 | $149K |
| A0436 | Rotary wing air mileage, per statute mile | <1% | 162 | $149K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 740 | $147K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 140 | $142K |
| J0897 | Injection, denosumab, 1 mg | <1% | 1,207 | $141K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,626 | $135K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,041 | $135K |
| 76830 | Ultrasound, transvaginal | <1% | 1,301 | $128K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 831 | $126K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,590 | $125K |
| 95708 | <1% | 310 | $123K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 1,636 | $122K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,548 | $121K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 345 | $118K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,029 | $115K |
| 95811 | <1% | 147 | $115K | |
| 31575 | <1% | 763 | $109K | |
| 58300 | <1% | 269 | $108K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 305 | $107K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,003 | $104K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 933 | $104K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,676 | $103K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,930 | $102K |
| 93308 | <1% | 558 | $102K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,488 | $100K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,474 | $99K |
| 43235 | <1% | 170 | $94K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 999 | $91K |
| 93975 | <1% | 492 | $90K | |
| Q3014 | Telehealth originating site facility fee | <1% | 5,061 | $90K |
| 97162 | <1% | 1,237 | $87K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 66 | $84K |
| 95911 | <1% | 214 | $84K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 32 | $83K |
| 96415 | <1% | 1,537 | $83K | |
| 96409 | <1% | 494 | $81K | |
| 93325 | <1% | 3,230 | $80K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,188 | $80K |
| 93017 | <1% | 494 | $76K | |
| 80061 | Lipid panel | <1% | 5,758 | $74K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 218 | $73K |
| 72197 | <1% | 207 | $73K | |
| 74018 | <1% | 1,538 | $70K | |
| 94726 | <1% | 476 | $69K | |
| 64615 | <1% | 358 | $69K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 430 | $69K |
| 97802 | <1% | 833 | $67K | |
| 95700 | <1% | 346 | $67K | |
| 72141 | <1% | 319 | $65K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,225 | $64K |
| 73630 | <1% | 1,235 | $64K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,546 | $63K |
| 74178 | <1% | 258 | $63K | |
| 76825 | <1% | 133 | $61K | |
| 74183 | <1% | 223 | $61K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,756 | $61K |
| 86850 | <1% | 2,392 | $61K | |
| 80050 | General health panel | <1% | 469 | $60K |
| 72100 | <1% | 944 | $60K | |
| 92134 | <1% | 2,004 | $60K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,751 | $59K |
| 11981 | <1% | 85 | $58K | |
| 97165 | <1% | 850 | $56K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 571 | $55K |
| 11102 | <1% | 426 | $54K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 625 | $54K |
| 58661 | <1% | 12 | $53K | |
| 71250 | <1% | 598 | $53K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 40 | $53K |
| 97161 | <1% | 711 | $51K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 519 | $51K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 192 | $51K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 442 | $49K |
| 76536 | <1% | 546 | $49K | |
| 77334 | <1% | 83 | $49K | |
| 74230 | <1% | 321 | $48K | |
| 72156 | <1% | 190 | $47K | |
| 93321 | <1% | 2,248 | $47K | |
| 72195 | <1% | 144 | $46K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,614 | $46K |
| 17110 | <1% | 409 | $46K | |
| 76801 | <1% | 408 | $45K | |
| 86780 | <1% | 3,158 | $44K | |
| 86901 | <1% | 2,392 | $44K | |
| 93970 | <1% | 239 | $42K | |
| 64493 | <1% | 66 | $42K | |
| 95076 | <1% | 89 | $42K | |
| 82728 | <1% | 4,167 | $42K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 1,232 | $41K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,911 | $41K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 772 | $40K |
| 92228 | <1% | 1,285 | $40K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 334 | $39K |
| 88342 | <1% | 519 | $38K | |
| 72158 | <1% | 164 | $38K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 197 | $38K |
| 93225 | <1% | 542 | $37K | |
| 92083 | <1% | 593 | $36K | |
| 93971 | <1% | 478 | $36K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,880 | $35K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,047 | $35K |
| 76820 | <1% | 421 | $35K | |
| 93350 | <1% | 104 | $35K | |
| 70491 | <1% | 237 | $35K | |
| 72170 | <1% | 517 | $34K | |
| 73030 | <1% | 717 | $34K | |
| 73610 | <1% | 741 | $34K | |
| 20611 | <1% | 198 | $34K | |
| 96367 | <1% | 840 | $33K | |
| 95886 | <1% | 390 | $33K | |
| 95115 | <1% | 1,051 | $33K | |
| 86003 | <1% | 546 | $32K | |
| 92579 | <1% | 333 | $32K | |
| 96411 | <1% | 543 | $32K | |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 97 | $32K |
| 31231 | <1% | 228 | $32K | |
| 85027 | <1% | 7,242 | $31K | |
| 11900 | <1% | 276 | $31K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,545 | $31K |
| 76642 | <1% | 462 | $31K | |
| 73560 | <1% | 797 | $31K | |
| A0434 | Specialty care transport (sct) | <1% | 56 | $31K |
| 90686 | <1% | 8,986 | $30K | |
| 84466 | <1% | 2,827 | $29K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 809 | $29K |
| 86923 | <1% | 271 | $29K | |
| 77066 | Tomosynthesis, mammo | <1% | 281 | $28K |
| 83970 | <1% | 891 | $28K | |
| 96450 | <1% | 98 | $28K | |
| 20552 | <1% | 195 | $28K | |
| 92201 | <1% | 738 | $28K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 43 | $27K |
| 77336 | <1% | 294 | $27K | |
| 86803 | <1% | 2,216 | $27K | |
| 88185 | <1% | 95 | $27K | |
| 70496 | <1% | 152 | $27K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 912 | $27K |
| 86481 | <1% | 342 | $26K | |
| 74240 | <1% | 184 | $26K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,232 | $25K |
| 83735 | <1% | 5,802 | $25K | |
| C8921 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete | <1% | 54 | $25K |
| 72040 | <1% | 504 | $25K | |
| 11104 | <1% | 117 | $24K | |
| 70486 | <1% | 293 | $24K | |
| 93296 | <1% | 992 | $24K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 115 | $24K |
| 92609 | <1% | 357 | $23K | |
| 77072 | <1% | 319 | $23K | |
| 84439 | <1% | 3,443 | $23K | |
| 92526 | <1% | 439 | $23K | |
| 76882 | <1% | 300 | $23K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 775 | $23K |
| 87497 | <1% | 602 | $23K | |
| 73562 | <1% | 471 | $23K | |
| 92610 | <1% | 419 | $23K | |
| 38222 | <1% | 13 | $23K | |
| 77080 | <1% | 232 | $23K | |
| 70543 | <1% | 63 | $22K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 91 | $22K |
| C1769 | Guide wire | <1% | 705 | $22K |
| 82784 | <1% | 1,690 | $21K | |
| 92552 | <1% | 292 | $21K | |
| 86235 | <1% | 355 | $21K | |
| 49452 | <1% | 18 | $21K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 546 | $21K |
| 84403 | <1% | 583 | $21K | |
| 88184 | <1% | 126 | $21K | |
| 83037 | <1% | 3,301 | $21K | |
| 74455 | <1% | 98 | $20K | |
| 96158 | <1% | 409 | $19K | |
| 73590 | <1% | 458 | $19K | |
| 83516 | <1% | 936 | $19K | |
| 96416 | <1% | 82 | $19K | |
| 73130 | <1% | 454 | $19K | |
| 96417 | <1% | 387 | $19K | |
| 73564 | <1% | 285 | $19K | |
| 73502 | <1% | 397 | $19K | |
| 87536 | <1% | 344 | $18K | |
| 73120 | <1% | 232 | $18K | |
| 36591 | <1% | 205 | $18K | |
| 20553 | <1% | 117 | $18K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 356 | $18K |
| 78264 | <1% | 65 | $18K | |
| 73110 | <1% | 356 | $18K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,527 | $18K |
| 77065 | Tomosynthesis, mammo | <1% | 206 | $18K |
| 20550 | <1% | 113 | $17K | |
| 86828 | <1% | 353 | $17K | |
| 92553 | <1% | 231 | $17K | |
| 87340 | <1% | 1,988 | $17K | |
| 76870 | <1% | 202 | $17K | |
| 82607 | <1% | 1,593 | $17K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 555 | $17K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 801 | $17K |
| 83880 | <1% | 821 | $17K | |
| 84702 | <1% | 1,352 | $17K | |
| 92133 | <1% | 722 | $17K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 183 | $17K |
| 90651 | <1% | 1,356 | $16K | |
| 97113 | <1% | 387 | $16K | |
| 87799 | <1% | 342 | $16K | |
| 73221 | <1% | 85 | $16K | |
| 83540 | <1% | 3,012 | $16K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 176 | $16K |
| 86140 | <1% | 4,784 | $16K | |
| 97166 | <1% | 248 | $16K | |
| 81025 | <1% | 2,574 | $16K | |
| 88307 | <1% | 226 | $15K | |
| 84484 | <1% | 2,179 | $15K | |
| 73090 | <1% | 285 | $15K | |
| 74019 | <1% | 248 | $15K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 691 | $15K |
| 43762 | <1% | 60 | $15K | |
| 72157 | <1% | 58 | $15K | |
| 88341 | <1% | 180 | $15K | |
| 82077 | <1% | 206 | $15K | |
| 92551 | <1% | 613 | $15K | |
| 90715 | <1% | 4,487 | $15K | |
| 74181 | <1% | 110 | $15K | |
| 78306 | <1% | 64 | $14K | |
| 84100 | <1% | 4,461 | $14K | |
| 85610 | <1% | 5,447 | $14K | |
| 31579 | <1% | 50 | $14K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 870 | $14K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 6,608 | $14K |
| 83690 | <1% | 3,811 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 305 | $14K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 644 | $14K |
| 87081 | <1% | 1,490 | $14K | |
| 92611 | <1% | 238 | $14K | |
| 92002 | <1% | 217 | $13K | |
| 72081 | <1% | 273 | $13K | |
| 83615 | <1% | 3,246 | $13K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 330 | $13K |
| 88112 | <1% | 385 | $13K | |
| 81268 | <1% | 69 | $12K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 373 | $12K |
| 86870 | <1% | 47 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,944 | $12K |
| 73552 | <1% | 330 | $12K | |
| 81001 | <1% | 5,404 | $11K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 528 | $11K |
| 10060 | <1% | 51 | $11K | |
| 92015 | Determination of refractive state | <1% | 8,514 | $11K |
| 73080 | <1% | 228 | $11K | |
| 96156 | <1% | 232 | $11K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 812 | $11K |
| 73070 | <1% | 206 | $11K | |
| 87631 | <1% | 87 | $11K | |
| 85652 | <1% | 5,609 | $11K | |
| 92582 | <1% | 149 | $11K | |
| 52000 | <1% | 40 | $10K | |
| 90670 | <1% | 717 | $10K | |
| 93320 | <1% | 237 | $10K | |
| 51728 | <1% | 29 | $10K | |
| 92555 | <1% | 530 | $10K | |
| 87077 | <1% | 1,804 | $10K | |
| 76512 | <1% | 127 | $10K | |
| 73140 | <1% | 225 | $10K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 160 | $10K |
| 70498 | <1% | 97 | $10K | |
| 81003 | <1% | 5,669 | $9K | |
| 84481 | <1% | 655 | $9K | |
| 94729 | <1% | 461 | $9K | |
| 80197 | <1% | 865 | $9K | |
| 86762 | <1% | 707 | $9K | |
| 82746 | <1% | 785 | $9K | |
| 84146 | <1% | 478 | $9K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 352 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 538 | $9K |
| 74174 | <1% | 28 | $9K | |
| 97804 | <1% | 317 | $8K | |
| 51798 | <1% | 384 | $8K | |
| 51702 | <1% | 139 | $8K | |
| 90734 | <1% | 452 | $8K | |
| 88304 | <1% | 415 | $8K | |
| 72082 | <1% | 157 | $8K | |
| 99495 | <1% | 121 | $8K | |
| 73620 | <1% | 151 | $8K | |
| 92593 | <1% | 681 | $8K | |
| 86580 | <1% | 314 | $8K | |
| 83655 | <1% | 637 | $8K | |
| 84460 | <1% | 2,096 | $8K | |
| 72070 | <1% | 124 | $7K | |
| 90732 | <1% | 474 | $7K | |
| 87653 | <1% | 231 | $7K | |
| 87186 | <1% | 1,246 | $7K | |
| 86160 | <1% | 484 | $7K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 360 | $7K |
| 86038 | <1% | 772 | $7K | |
| 76885 | <1% | 76 | $7K | |
| 84550 | <1% | 2,092 | $7K | |
| 85046 | <1% | 1,745 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 213 | $7K |
| 76818 | <1% | 53 | $7K | |
| 58301 | <1% | 24 | $7K | |
| 83605 | <1% | 1,229 | $7K | |
| 99173 | <1% | 525 | $7K | |
| 10005 | <1% | 14 | $7K | |
| 49083 | <1% | 18 | $7K | |
| 99152 | <1% | 514 | $7K | |
| 86706 | <1% | 749 | $7K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 96 | $7K |
| 51705 | <1% | 62 | $6K | |
| 80069 | <1% | 984 | $6K | |
| 51741 | <1% | 111 | $6K | |
| 82670 | <1% | 268 | $6K | |
| 82570 | <1% | 1,517 | $6K | |
| 83001 | <1% | 393 | $6K | |
| 82962 | <1% | 3,402 | $6K | |
| 97163 | <1% | 61 | $6K | |
| 86335 | <1% | 292 | $6K | |
| 73100 | <1% | 118 | $6K | |
| 77073 | <1% | 98 | $6K | |
| 86618 | <1% | 387 | $6K | |
| 86704 | <1% | 565 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,789 | $6K |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 158 | $6K |
| 77300 | <1% | 30 | $6K | |
| 82565 | <1% | 1,878 | $6K | |
| 70360 | <1% | 97 | $6K | |
| 11721 | <1% | 185 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 348 | $6K |
| 87070 | <1% | 1,204 | $6K | |
| 80143 | <1% | 88 | $6K | |
| 91010 | <1% | 13 | $5K | |
| 73060 | <1% | 119 | $5K | |
| 87040 | <1% | 718 | $5K | |
| 87505 | <1% | 66 | $5K | |
| 83520 | <1% | 156 | $5K | |
| X0592 | <1% | 162 | $5K | |
| 86334 | <1% | 365 | $5K | |
| 84145 | <1% | 447 | $5K | |
| 97164 | <1% | 102 | $5K | |
| 91200 | <1% | 45 | $5K | |
| 70480 | <1% | 47 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 376 | $5K |
| 83002 | <1% | 328 | $5K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 426 | $5K |
| 76942 | <1% | 245 | $5K | |
| 82950 | <1% | 929 | $5K | |
| 87102 | <1% | 798 | $5K | |
| 93298 | <1% | 114 | $5K | |
| 84156 | <1% | 1,659 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 26 | $5K |
| 87205 | <1% | 1,733 | $5K | |
| 82024 | <1% | 145 | $4K | |
| 83993 | <1% | 150 | $4K | |
| 82043 | <1% | 990 | $4K | |
| 82657 | <1% | 156 | $4K | |
| 82105 | <1% | 379 | $4K | |
| 96368 | <1% | 212 | $4K | |
| 36592 | <1% | 45 | $4K | |
| 80076 | <1% | 641 | $4K | |
| 92558 | <1% | 408 | $4K | |
| 80320 | <1% | 37 | $4K | |
| 83883 | <1% | 320 | $4K | |
| 97542 | <1% | 142 | $4K | |
| 11982 | <1% | 13 | $4K | |
| 94375 | <1% | 27 | $4K | |
| 96112 | <1% | 28 | $4K | |
| 87493 | <1% | 144 | $4K | |
| 84075 | <1% | 1,129 | $4K | |
| 84270 | <1% | 216 | $4K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 388 | $4K |
| 64643 | <1% | 202 | $4K | |
| 84153 | <1% | 242 | $4K | |
| 86361 | <1% | 206 | $4K | |
| V5266 | Battery for use in hearing device | <1% | 201 | $4K |
| 86225 | <1% | 390 | $4K | |
| 96402 | <1% | 103 | $4K | |
| 36416 | <1% | 1,460 | $4K | |
| 82977 | <1% | 711 | $4K | |
| 82378 | <1% | 319 | $4K | |
| 85379 | <1% | 603 | $4K | |
| 82247 | <1% | 1,216 | $4K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,657 | $4K |
| 84450 | <1% | 936 | $4K | |
| 84425 | <1% | 194 | $4K | |
| 57454 | <1% | 12 | $4K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 14 | $3K |
| 97116 | <1% | 345 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 72 | $3K |
| 72146 | <1% | 43 | $3K | |
| 83020 | <1% | 301 | $3K | |
| 74221 | <1% | 25 | $3K | |
| 85730 | <1% | 1,023 | $3K | |
| A4215 | Needle, sterile, any size, each | <1% | 345 | $3K |
| 82397 | <1% | 307 | $3K | |
| 82951 | <1% | 215 | $3K | |
| 11719 | <1% | 112 | $3K | |
| 51701 | <1% | 37 | $3K | |
| 92652 | <1% | 14 | $3K | |
| 64644 | <1% | 14 | $3K | |
| 95819 | <1% | 13 | $3K | |
| 90723 | <1% | 373 | $3K | |
| 82550 | <1% | 712 | $3K | |
| 86360 | <1% | 72 | $3K | |
| 84165 | <1% | 438 | $3K | |
| 82533 | <1% | 230 | $3K | |
| 76827 | <1% | 43 | $3K | |
| 82627 | <1% | 156 | $3K | |
| 93925 | <1% | 20 | $3K | |
| 73700 | <1% | 27 | $3K | |
| 95910 | <1% | 12 | $3K | |
| 91037 | <1% | 12 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 117 | $3K |
| 95909 | <1% | 12 | $3K | |
| 88302 | <1% | 166 | $3K | |
| 84144 | <1% | 150 | $3K | |
| 93356 | <1% | 366 | $3K | |
| 82785 | <1% | 223 | $3K | |
| 86147 | <1% | 70 | $3K | |
| 96376 | <1% | 1,258 | $3K | |
| 87529 | <1% | 85 | $3K | |
| 76821 | <1% | 39 | $3K | |
| 87338 | <1% | 177 | $2K | |
| 96116 | <1% | 13 | $2K | |
| A0998 | Ambulance response and treatment, no transport | <1% | 26 | $2K |
| 11720 | <1% | 105 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 14 | $2K |
| 64405 | <1% | 13 | $2K | |
| 86039 | <1% | 267 | $2K | |
| 86200 | <1% | 245 | $2K | |
| 86359 | <1% | 72 | $2K | |
| 82248 | <1% | 523 | $2K | |
| 76937 | <1% | 60 | $2K | |
| 97760 | <1% | 60 | $2K | |
| 93880 | <1% | 17 | $2K | |
| 20605 | <1% | 13 | $2K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 136 | $2K |
| 86376 | <1% | 189 | $2K | |
| 99385 | <1% | 186 | $2K | |
| 58100 | <1% | 13 | $2K | |
| 87210 | <1% | 353 | $2K | |
| 83498 | <1% | 119 | $2K | |
| 86355 | <1% | 64 | $2K | |
| 80179 | <1% | 84 | $2K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 400 | $2K |
| 86787 | <1% | 136 | $2K | |
| 88720 | <1% | 332 | $2K | |
| 99381 | <1% | 115 | $2K | |
| J3490 | Unclassified drugs | <1% | 1,480 | $2K |
| 83525 | <1% | 168 | $2K | |
| 51784 | <1% | 30 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,009 | $2K |
| 92504 | <1% | 482 | $2K | |
| C1729 | Catheter, drainage | <1% | 122 | $2K |
| 86592 | <1% | 459 | $2K | |
| 86357 | <1% | 59 | $2K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 248 | $2K |
| 80177 | <1% | 164 | $2K | |
| 86431 | <1% | 413 | $2K | |
| 96132 | <1% | 14 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 155 | $2K |
| 12001 | <1% | 27 | $2K | |
| 77002 | <1% | 29 | $2K | |
| 70250 | <1% | 32 | $2K | |
| 86146 | <1% | 52 | $2K | |
| 59430 | <1% | 42 | $2K | |
| 87075 | <1% | 301 | $2K | |
| 82150 | <1% | 367 | $2K | |
| 84630 | <1% | 162 | $2K | |
| 84305 | <1% | 103 | $2K | |
| 89051 | <1% | 373 | $1K | |
| 92523 | <1% | 12 | $1K | |
| 82947 | <1% | 427 | $1K | |
| 84520 | <1% | 707 | $1K | |
| 84207 | <1% | 27 | $1K | |
| 87899 | <1% | 69 | $1K | |
| 90647 | <1% | 483 | $1K | |
| 80164 | <1% | 108 | $1K | |
| 72131 | <1% | 27 | $1K | |
| 82232 | <1% | 109 | $1K | |
| 86141 | <1% | 126 | $1K | |
| 83921 | <1% | 73 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $1K |
| G0009 | Administration of pneumococcal vaccine | <1% | 65 | $1K |
| 92583 | <1% | 54 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 122 | $1K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 302 | $1K |
| 86021 | <1% | 92 | $1K | |
| 94761 | <1% | 12 | $998.72 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,635 | $986.36 |
| 99386 | <1% | 43 | $949.54 | |
| 88172 | <1% | 14 | $945.37 | |
| 69209 | <1% | 27 | $940.84 | |
| 85018 | <1% | 429 | $919.73 | |
| 88173 | <1% | 32 | $915.45 | |
| 86708 | <1% | 84 | $915.21 | |
| 82103 | <1% | 38 | $891.56 | |
| 80175 | <1% | 75 | $884.64 | |
| 82040 | <1% | 391 | $879.77 | |
| 96113 | <1% | 27 | $861.37 | |
| 82330 | <1% | 103 | $855.57 | |
| 0081A | <1% | 14 | $845.91 | |
| 85384 | <1% | 109 | $827.53 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,401 | $825.49 |
| 90662 | <1% | 419 | $815.28 | |
| 96161 | <1% | 92 | $807.10 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,119 | $804.63 |
| 87206 | <1% | 266 | $789.19 | |
| 82952 | <1% | 174 | $777.90 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 28 | $749.08 |
| 90746 | <1% | 54 | $725.92 | |
| 17250 | <1% | 13 | $716.86 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 665 | $715.10 |
| 90750 | <1% | 41 | $712.92 | |
| 84703 | <1% | 151 | $712.85 | |
| 87106 | <1% | 83 | $704.61 | |
| 88313 | <1% | 12 | $653.32 | |
| 88300 | <1% | 154 | $624.33 | |
| 3078F | <1% | 71,131 | $621.57 | |
| 71271 | <1% | 12 | $613.40 | |
| 84446 | <1% | 54 | $613.06 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,314 | $601.93 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14 | $591.52 |
| 81002 | <1% | 184 | $587.62 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,373 | $586.98 |
| 90681 | <1% | 86 | $585.29 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,358 | $577.28 |
| 86696 | <1% | 29 | $576.06 | |
| 82310 | <1% | 189 | $575.93 | |
| 82803 | <1% | 73 | $572.24 | |
| 85240 | <1% | 36 | $535.22 | |
| 87116 | <1% | 109 | $509.87 | |
| 86800 | <1% | 37 | $508.14 | |
| 86645 | <1% | 26 | $505.76 | |
| 82507 | <1% | 16 | $486.46 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,174 | $480.20 |
| 87147 | <1% | 136 | $475.29 | |
| 86694 | <1% | 29 | $474.66 | |
| 86644 | <1% | 29 | $467.79 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,628 | $458.70 |
| 90480 | <1% | 25 | $456.66 | |
| 73600 | <1% | 14 | $454.78 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,617 | $445.77 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,038 | $430.12 |
| 93926 | <1% | 13 | $426.66 | |
| 86695 | <1% | 30 | $421.64 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,314 | $411.83 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,383 | $398.75 |
| 84300 | <1% | 85 | $395.53 | |
| 51600 | <1% | 13 | $371.74 | |
| 92592 | <1% | 63 | $352.07 | |
| 80051 | <1% | 101 | $349.84 | |
| 82340 | <1% | 50 | $332.06 | |
| 84157 | <1% | 144 | $331.73 | |
| 82945 | <1% | 133 | $320.46 | |
| 87015 | <1% | 105 | $315.06 | |
| J1815 | Injection, insulin, per 5 units | <1% | 852 | $313.62 |
| 86341 | <1% | 27 | $310.75 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 703 | $307.43 |
| 95873 | <1% | 473 | $302.70 | |
| 82164 | <1% | 28 | $299.10 | |
| 90633 | <1% | 227 | $282.93 | |
| 83521 | <1% | 18 | $282.58 | |
| 87045 | <1% | 44 | $276.50 | |
| 87046 | <1% | 43 | $276.50 | |
| 86665 | <1% | 12 | $273.27 | |
| 83945 | <1% | 16 | $260.80 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,409 | $252.56 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,322 | $252.40 |
| 84681 | <1% | 14 | $250.62 | |
| 0352U | <1% | 13 | $242.48 | |
| 81015 | <1% | 141 | $229.28 | |
| 88311 | <1% | 47 | $220.31 | |
| 85598 | <1% | 14 | $217.46 | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 95 | $214.50 |
| 84105 | <1% | 35 | $213.22 | |
| 99417 | Prolong home eval add 15m | <1% | 47 | $210.85 |
| 86301 | <1% | 15 | $209.96 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 27 | $206.40 |
| 84590 | <1% | 28 | $204.55 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 365 | $201.26 |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 15 | $196.48 |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 105 | $192.46 |
| 82436 | <1% | 29 | $184.75 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 691 | $184.56 |
| 94760 | <1% | 12 | $182.20 | |
| 86664 | <1% | 12 | $182.02 | |
| 85246 | <1% | 12 | $176.39 | |
| 88312 | <1% | 12 | $174.54 | |
| 82390 | <1% | 13 | $167.16 | |
| 84560 | <1% | 29 | $162.90 | |
| 85999 | <1% | 95 | $161.36 | |
| 84133 | <1% | 30 | $158.01 | |
| 82010 | <1% | 48 | $152.40 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 82 | $151.74 |
| 83986 | <1% | 42 | $150.23 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,816 | $128.08 |
| 82140 | <1% | 30 | $125.75 | |
| 80201 | <1% | 18 | $125.16 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,002 | $122.92 |
| 85613 | <1% | 14 | $117.62 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,014 | $109.54 |
| 82525 | <1% | 13 | $105.56 | |
| 84392 | <1% | 16 | $90.88 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 173 | $78.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 438 | $77.80 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 965 | $76.98 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 271 | $57.97 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 527 | $57.82 |
| 86308 | <1% | 13 | $53.59 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 322 | $53.42 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 140 | $48.47 |
| 85660 | <1% | 12 | $42.87 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,327 | $41.72 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 21 | $30.24 |
| V5275 | Ear impression, each | <1% | 27 | $28.80 |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 27 | $23.04 |
| J9250 | Methotrexate sodium, 5 mg | <1% | 23 | $21.26 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 145 | $17.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 80 | $12.28 |
| 85014 | <1% | 13 | $11.90 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 277 | $9.84 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 32 | $7.31 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,878 | $4.40 |
| 3074F | <1% | 80,818 | $0.16 | |
| 3008F | <1% | 57,548 | $0.12 | |
| 3077F | <1% | 9,507 | $0.02 | |
| 3075F | <1% | 10,410 | $0.02 | |
| 3079F | <1% | 20,308 | $0.02 | |
| 1111F | <1% | 809 | $0.02 | |
| 3080F | <1% | 7,042 | $0.01 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 554 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 868 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 283 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 451 | $0.00 |
| 3051F | 0% | 443 | $0.00 | |
| 3046F | 0% | 475 | $0.00 | |
| 90700 | 0% | 28 | $0.00 | |
| 91321 | 0% | 406 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 139 | $0.00 |
| 91322 | 0% | 266 | $0.00 | |
| 91320 | 0% | 38 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,196 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 367 | $0.00 |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 27 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 222 | $0.00 |
| 0100U | 0% | 61 | $0.00 | |
| 90380 | 0% | 34 | $0.00 | |
| 90678 | 0% | 40 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 17 | $0.00 |
| 91308 | 0% | 87 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 14 | $0.00 |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 0% | 23 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 13 | $0.00 |
| J0475 | Injection, baclofen, 10 mg | 0% | 12 | $0.00 |
| 3044F | 0% | 3,169 | $0.00 | |
| 90677 | 0% | 590 | $0.00 | |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 0% | 331 | $0.00 |
| 3052F | 0% | 284 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 65 | $0.00 |
| 3061F | 0% | 121 | $0.00 | |
| 90656 | 0% | 1,241 | $0.00 | |
| 91318 | 0% | 19 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 177 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 43 | $0.00 |
| J2350 | Injection, ocrelizumab, 1 mg | 0% | 28 | $0.00 |
| 3060F | 0% | 95 | $0.00 | |
| 90381 | 0% | 12 | $0.00 | |
| J9299 | Injection, nivolumab, 1 mg | 0% | 65 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 13 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 33 | $0.00 |
| J0178 | Injection, aflibercept, 1 mg | 0% | 12 | $0.00 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKENNA, DONALD (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| The Milton S. Hershey Medical Center Physicians Group | Hershey, PA | $26.66M |
| The Milton S Hershey Medical Center | Hershey, PA | $3.54M |
| The Milton S. Hershey Medical Center | Hershey, PA | $2.15M |
| The Milton S. Hershey Medical Center | Hershey, PA | $377K |
| Penn State Health Holy Spirit Medical Center | Camp Hill, PA | $12K |
| The Milton S Hershey Medical Center Physicians Group | Hershey, PA | $6K |
| The Milton S Hershey Medical Center Physicians Group | Hershey, PA | $6K |
| The Milton S. Hershey Medical Center | Hershey, PA | $3K |
| The Milton S Hershey Medical Center Physicians Group | Hershey, PA | $1K |
| The Milton S Hershey Medical Center Physicians Group | Hershey, PA | $1K |
| The Milton S. Hershey Medical Center Physician Group | Harrisburg, PA | $1K |
| The Milton S Hershey Medical Center Physician Group | Hershey, PA | $137.12 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.